7:13AM Auxilium Pharma misses by $0.01, misses on revs; guides FY11 revs in-line (AUXL) 23.44 : Reports Q1 (Mar) loss of $0.25 per share, $0.01 worse than the Thomson Reuters consensus of ($0.24); revenues rose 28.6% year/year to $58.4 mln vs the $61.1 mln consensus. Co issues in-line guidance for FY11, sees FY11 revs of $259-281 mln vs. $268.66 mln Thomson Reuters consensus. Co sees R & D Expense of $60-70 mln. Additionally, as a result of the $30 mln in regulatory milestones received from Pfizer and the $15 mln in milestones received from Asahi Kasei Pharma, the co is increasing full year 2011 XIAFLEX contract and ex-U.S. revenues from the previously stated guidance of a range of $5-7 mln to a range of $9-11 mln. The increase in XIAFLEX contract and ex-U.S. revenues changes full year 2011 net loss guidance from the previously stated guidance of a range of ($5) -($35) mln to a range of ($41) to ($31) mln for the year
surf's up......crikey